| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58160-0830-32 | 58160-0830 | Human Papillomavirus Bivalent Vaccine, Recombinant | Cervarix | 20.0 ug/.5mL, 20.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Oct 16, 2009 | Sep 3, 2013 | No Longer Used |
| 00591-2292-30 | 00591-2292 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 20, 2015 | Apr 30, 2019 | No Longer Used |
| 65162-0750-03 | 65162-0750 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 2, 2015 | In Use | |
| 00006-4119-01 | 00006-4119 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | In Use | |
| 00006-4121-02 | 00006-4121 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | In Use | |
| 00003-5710-21 | 00003-5710 | Iberdomide | ZENBEXUS | 1.0 mg/1 | Chemotherapy | Protein Degrader | Cereblon | Oral | Aug 13, 2026 | In Use | |
| 00003-5700-21 | 00003-5700 | Iberdomide | ZENBEXUS | 0.75 mg/1 | Chemotherapy | Protein Degrader | Cereblon | Oral | Aug 13, 2026 | In Use | |
| 84043-0100-30 | 84043-0100 | Vepdegestrant | VEPPANU | 100.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | May 1, 2026 | In Use | |
| 71332-0007-30 | 71332-0007 | Vepdegestrant | VEPPANU | 100.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | Jun 16, 2026 | In Use | |
| 84043-0200-30 | 84043-0200 | Vepdegestrant | VEPPANU | 200.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, cereblon/CRBN | Oral | May 1, 2026 | In Use | |
| 71332-0008-30 | 71332-0008 | Vepdegestrant | VEPPANU | 200.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | Jun 16, 2026 | In Use | |
| 00007-3262-01 | 00007-3262 | Tositumomab, Iodine I-131 | Bexxar Therapeutic | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Feb 20, 2014 | No Longer Used | ||
| 00007-3260-31 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Nov 28, 2014 | No Longer Used | ||
| 68152-0104-04 | 68152-0104 | Ibritumomab Tiuxetan | Zevalin | Immunotherapy | Radioimmunotherapy | CD20 | Feb 19, 2002 | Dec 3, 2011 | No Longer Used | ||
| 68152-0103-03 | 68152-0103 | Ibritumomab Tiuxetan | Zevalin | Immunotherapy | Radioimmunotherapy | CD20 | Feb 19, 2002 | Oct 26, 2020 | In Use | ||
| 00007-3261-01 | 00007-3261 | Tositumomab, Iodine I-131 | Bexxar Dosimetric | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Feb 13, 2014 | No Longer Used | ||
| 00007-3260-36 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | Jul 15, 2009 | Nov 28, 2014 | No Longer Used | ||
| 69945-0451-02 | 69945-0451 | sodium iodide, i-131 | Sodium Iodide I-131 | 25.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 69945-0451-03 | 69945-0451 | sodium iodide, i-131 | Sodium Iodide I-131 | 25.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 57902-0860-03 | 57902-0860 | Samarium SM 153 Lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
| 00019-9452-05 | 00019-9452 | Sodium Iodide I-131 | Sodium Iodide I-131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Jan 25, 2012 | Jul 1, 2017 | No Longer Used |
| 69488-0010-61 | 69488-0010 | Lutetium Lu 177 vipivotide tetraxetan | PLUVICTO | 27.0 mCi/mL | Radiopharmaceutical | Radiopharmaceutical | PSMA | Intravenous | Mar 23, 2022 | In Use | |
| 69945-0450-03 | 69945-0450 | sodium iodide, i-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 00019-9450-01 | 00019-9450 | Sodium Iodide I-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Aug 22, 2011 | Jul 1, 2017 | No Longer Used |
| 00019-9452-08 | 00019-9452 | Sodium Iodide I-131 | Sodium Iodide I-131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Jan 25, 2012 | Jul 1, 2017 | No Longer Used |
Found 12611 results — Export these results
Home